TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02019953

Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.

Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.

Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.

Intervention type: OTHER
Group type: OTHER
Intervention: Walking
Description: The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Lifestyles Education
Description: Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
Study: NCT00175916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam (ucb 34714)
Description: 10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
Study: NCT02936518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual frenotomy and/or maxillary labial frenectomy
Study: NCT00548626

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single needle
Description: Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
Study: NCT02988089

Intervention type: DRUG
Group type: OTHER
Intervention: proton pump inhibitor (PPI) and Colloidal Bismuth Pectin
Description: all patients need these two drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and clarithromycin or amoxicillin and furazolidone
Description: patients in the 6 antibiotics dependant group will use these intervention.
Study: NCT04465773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: continuous infusion, target concentration adjusted to maintain bispectral index between 45 and 55

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil, Ultiva®
Description: continuous infusion, target concentration 1 ng/ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tetanic stimulations
Description: 10-20-30-40-50-60 milliamps, 5 seconds, 100 Hertz 2 minutes between stimulations delivered via the standard neuromuscular blocking agents monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VideoAlgesiGraph
Description: non invasive infrared camera placed in front of the left eye of the patients during the study period, connected to a laptop. No part of the device touches the eye.
Study: NCT01558180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Care Management
Description: series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: educational handouts on pediatric insomnia
Study: NCT04164914

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Soluble prebiotic fiber (resistant dextrin 14 g/d x 4 weeks)
Study: NCT03876418

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intra-abdominal Pressure
Description: Aggressive screening, prevention and treatment of intra-abdominal hypertension
Study: NCT03900065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preconditioning
Description: Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
Study: NCT02378350

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis treatment (no specific device is defined)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis treatment (no specific drug is defined)
Study: NCT05549908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared
Study: NCT01987973

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Rotator Cuff Repair
Description: This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Rotator Cuff Repair with Allograft Augmentation
Description: Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
Study: NCT02988089

Intervention type: DRUG
Group type: OTHER
Intervention: amoxicillin and furazolidone or amoxicillin and tetracycline
Description: salvage therapy for negative culture when the results of culture are negative

Intervention type: DRUG
Group type: OTHER
Intervention: amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
Description: salvage therapy for failed eradication if failed with AST guided eradication therapy
Study: NCT05598554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Chair-based yoga with telerehabilitation was applied to the study group for 45 minutes a day, 2 days a week, for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information
Description: A one-session training was provided on the effects of exercise on quality of life.
Study: NCT03881956

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health-promoting lifestyle education program
Description: The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
Study: NCT00942435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical prophylaxis
Description: The investigator will determine the method of mechanical prophylaxis
Study: NCT00839592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electroacupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Study: NCT02203214

Intervention type: DEVICE
Intervention: Ligamys
Description: All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
Study: NCT04166448

Intervention type: OTHER
Intervention: Fetal MRI
Description: The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)

Intervention type: OTHER
Intervention: Fetal MRI
Description: The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
Study: NCT03155321

Intervention type: OTHER
Intervention: It's an observational study - no intervention is planned
Description: No intervention is planned
Study: NCT01043835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted gastrectomy
Description: A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
Study: NCT01340768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: One 100 mg tablet taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
Study: NCT03591523

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MR angiography
Description: Quantitative MR angiography: A standard axial 3-dimensional time-of-flight (TOF) MRA of intracranial and cervical arteries will be obtained. Then, the acquired images will be transmitted to the workstation to reconstruct 3D surface-rendered vessel images. After determining optimal perpendicular scan plane and setting the baseline coordinates , retrospectively gated, fast 2-dimensional phase-contrast sequence will be performed. Velocity encoding will be automatically adjusted by NOVA software.
Study: NCT00405054

Intervention type: DRUG
Group type: OTHER
Intervention: MK0457
Description: IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
Study: NCT00548626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple needle
Description: Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
Study: NCT03591523

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex sonography
Description: Duplex sonography of cervical arteries will be performed using 5 - 12 MHz linear duplex probe and transcranial color-coded duplex sonography will be performed using 2 - 5 MHz transcranial duplex probe. Peak systolic velocity, end diastolic celocity, mean blood flow velocity and arterial diameter will be measured with automatic calculation of blood flow velocity in each arterial segment.
Study: NCT00555360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HITCM+CP
Description: Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HITCM only
Description: Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
Study: NCT03884452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Tablets taken orally once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Tablets taken orally once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Tablets taken orally once daily in the morning
Study: NCT03338816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givosiran
Description: Givosiran by SC
Study: NCT03884452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Tablets taken orally once daily in the morning or evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Tablets taken orally once daily in the morning or evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Tablets taken orally once daily in the morning or evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Tablet taken orally once daily in the morning or evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Tablet taken orally once daily in the morning or evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Tablet taken orally once daily in the morning or evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Tablet taken orally once daily in the morning or evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ezetimibe
Description: Tablets taken orally once daily in the morning or evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ezetimibe
Description: Tablets taken orally once daily in the morning or evening
Study: NCT00437840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
Study: NCT03338816

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Givosiran
Description: Givosiran by SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (normal saline \[0.9% NaCl\]) by SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (normal saline \[0.9% NaCl\]) by SC
Study: NCT02331745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Description: Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
Study: NCT00437840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive single oral dose of matching placebo tablet to GSK598809.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive single oral dose of matching placebo tablet to GSK598809.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive single oral dose of matching placebo tablet to GSK598809.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive single oral dose of matching placebo tablet to GSK598809.
Study: NCT00801099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid
Description: single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
Study: NCT03506984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold Inspiration Muscle Training Device
Description: Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Bicycle Ergometer
Description: Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
Study: NCT03802253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding(TRF)
Description: Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm) in the first 6 months. 6 months later, Participants will receive a diet of 1200-1500kcal/d without a restriction of feeding time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Calorie Diet (RCD)
Description: Participants will receive a diet of 1200-1500kcal/d and keep their usual eating pattern.
Study: NCT00941148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin (2000 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin (2000 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin (2000 mg/day)
Study: NCT02845765

Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer (DVA)

Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer (DVA)

Intervention type: DRUG
Intervention: Phosphodiesterase type 5 Inhibitor (PDE5I)
Study: NCT04790838

Intervention type: DRUG
Intervention: Test
Description: 2 inhalations of Test and Reference product in each study period

Intervention type: DRUG
Intervention: Reference
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT04259463

Intervention type: PROCEDURE
Intervention: Third molars extraction
Description: Third molars extractions with concious sedation or general anesthesia

Intervention type: PROCEDURE
Intervention: Third molars extraction
Description: Third molars extractions with concious sedation or general anesthesia